Annual Newsletter 2017

Download a copy here. Newsletter_Autumn_2017.pdf

Latest

3P - Post Doc Seminar - 21 April

Please join Nora Bengoa-Vergniory, Research fellow at Oxford University discussing 'CLR01 protects dopaminergic neurons in vitro and in vivo in mouse and human models' and Anke Van der Perren, Postdoc at KU Leuven presenting 'In vivo characterization of distinct patient-derived alpha-synuclein strains'
3P - Post Doc Seminar - 16 April

Please join Sara Saez Atienzar discussing 'genetic analysis of amyotrophic lateral sclerosis identifies contributing pathways and cell types' and Nikhil Panicker who will present on how Parkin limits priming and activation of the NLRP3 inflammasome in dopaminergic neurons
3P - Post Doc Seminar - 14 April

Please join the 3P Seminars as Lynne Krohn presents on REM Sleep Behavior Disorder genetics for early detection & subtyping of Parkinson and Kariem Ezzat discusses Heterogeneous Nucleation and Loss-Of-Function (HEN-LOF) Mechanisms in Amyloid Pathologies
Membrane Trafficking in Parkinson's - 9 April

Please join: Dorien Roosen, former postdoc with the NIH and Leibniz Forschüngsinstitut für Molekulare Pharmakologie, NIH, NIA, Laboratory of Neurogenetics; Luis Bonet-Ponce, postdoc with the NIH and Adamantios Mamais, former postdoc at NIH in this inaugural seminar

The STEADY-PD Trial Results

The results of the Phase lll STEADY-PD clinical trial have now been published.
Further Support for the 'Repurposed' Simvastatin

Statins are a well characterised class of medication that are used to lower cholesterol levels in the body. Evidence strongly suggests certain statins have been for use as a potential treatment for Parkinson's, this particularly applies to a statin called simvastatin
Please Support The Cure Parkinson’s Trust’s Charity Appeal on BBC Radio 4

We are delighted that Paul Mayhew-Archer, co-writer of The Vicar of Dibley, will be presenting our BBC Radio 4 Appeal on 12 April (Easter Sunday) - Please tune in!
A Better Delivery of Dopamine

Lower levels of dopamine are associated with the motor symptoms of the condition - slowness and rigidity of movement. New research, led by Prof. David Devos, proposes a continuous delivery of a more stable form of dopamine directly into the brain.
#ParkinsonsTogether

We want to hear your stories, from the Parkinson’s community, about the creative ways you are keeping safe, motivated and upbeat at home during this time...
3P: Parkinson Postdoc Program Seminars

Calling early career scientists! Feeling socially distanced? Maybe quarantined? Wondering what you can do to further your career during this time? How about presenting and discussing your research with other early career neuroscientists who are in the same boat!
PD Frontline

Many drugs developed for Parkinson's are targeted at specific genes, such as the GBA and the LRRK2 gene. To test whether these drugs work, we need to identify people with abnormalities in these genes who can be enrolled in clinical trials.
Time to Re-nurture Neurturin?

Results of a disappointing clinical trial in 2013 testing a gene therapy for Parkinson's have been re-investigated with some new and important implications for future trials in the field.
News: COVID-19

First and foremost in these difficult times we hope that everyone stays safe. This is a fast-moving situation causing disruption and anxiety and CPT is monitoring and responding to the unprecedented COVID-19 crisis as it evolves.
Multi-Arm Multi-Stage Trials for Parkinson's

Most clinical trials involve a single therapy, being tested against a 'placebo' or control treatment for a fixed period of time. The MAMS study technique explores a potential new trial design for Parkinson's

Breakthrough in stem cell treatment for Parkinson's

In a major breakthrough for the treatment of Parkinson's, researchers working with laboratory rats show it is possible to make dopamine cells from embryonic stem cells and transplant them into the brain.
Tom Isaacs

We are devastated to announce that Tom Isaacs, President and Co-founder of The Cure Parkinson’s Trust (CPT) died on Wednesday morning (31st May). Tom’s passing was unexpected and swift.
New Evidence Suggests Parkinson's Might Not Start in The Brain

A new study adds to a raft of new evidence which suggests Parkinson's starts in the gut...
Science news

Read the latest Parkinson's science and research news here.
Trials - Repurposed Drugs

Our International Linked Clinical Trials initiative (iLCT) identifies potential new treatments to slow, stop or reverse Parkinson’s disease by 'repurposing' or repositioning drugs that are approved to treat other conditions.
Apply for Funding
The NAC Trial - the facts
Our story
Diabetes Drug Potential Disease-Modifying Therapy

The study, published in The Lancet and funded by The Michael J. Fox Foundation for Parkinson’s Research (MJFF), supported by CPT found that people with Parkinson’s treated with Exenatide for one year performed better in motor tests than those on placebo.
Alpha-synuclein and Parkinson's

Science news

Read the latest Parkinson's science and research news here. Read more

The Cure Collective

The Cure Collective is an opportunity to join like-minded individuals who are committed to help drive forward the quest to find a cure for Parkinson’s... Read more

Our Annual Review 2019

Our Annual Review 2019 - your online publication here... Read more